BioCentury
ARTICLE | Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

October 22, 2018 9:15 PM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to methotrexate.

GSK did not respond in time for publication regarding next steps, but said the results support further clinical development of the product to treat RA...